Method Article

Preparation and Characterization of Novel HDL-mimicking Nanoparticles for Nerve Growth Factor Encapsulation

7.9K views

⸱

DOI:

10.3791/55584

⸱

May 22nd, 2017

 , 
1Department of Pharmaceutical Sciences, College of Pharmacy, University of North Texas Health Science Center

In This Article

Summary

Simple homogenization was used to prepare novel, high-density, lipoprotein-mimicking nanoparticles to encapsulate nerve growth factor. Challenges, detailed protocols for nanoparticle preparation, in vitro characterization, and in vivo studies are described in this article.

Abstract

The objective of this article is to introduce preparation and characterization methods for nerve growth factor (NGF)-loaded, high-density, lipoprotein (HDL)-mimicking nanoparticles (NPs). HDLs are endogenous NPs and have been explored as vehicles for the delivery of therapeutic agents. Various methods have been developed to prepare HDL-mimicking NPs. However, they are generally complicated, time consuming, and difficult for industrial scale-up. In this study, one-step homogenization was used to mix the excipients and form the prototype NPs. NGF is a water-soluble protein of 26 kDa. To facilitate the encapsulation of NGF into the lipid environment of HDL-mimicking NPs, protamine USP was used to form an ion-pair complex with NGF to neutralize the charges on the NGF surface. The NGF/protamine complex was then introduced into the prototype NPs. Apolipoprotein A-I was finally coated on the surface of the NPs. NGF HDL-mimicking NPs showed preferable properties in terms of particle size, size distribution, entrapment efficiency, in vitro release, bioactivity, and biodistribution. With the careful design and exploration of homogenization in HDL-mimicking NPs, the procedure was greatly simplified, and the NPs were made scalable. Moreover, various challenges, such as separating unloaded NGF from the NPs, conducting reliable in vitro release studies, and measuring the bioactivity of the NPs, were overcome.

Introduction

Macromolecules, such as proteins, peptides, and nucleic acids, have been emerging as promising medications and have gained considerable attention in past decades1,2. Due to their high efficacy and specific action modes, they exhibit great therapeutic potential for the treatments of cancer, immune disease, HIV, and related conditions3,4. However, physiochemical properties, such as their large molecular size, three-dimensional structure, surface charges, and hydrophilic nature, make the in vivo delivery of these macromolecules very challenging. This considerably impedes their clinical use4. Recent advancements in drug delivery systems, such as microparticles, polymer nanoparticles (NPs), liposomes, and lipid NPs, overcame these challenges and significantly improved the in vivo delivery of macromolecules. However, some drawbacks regarding these delivery cargoes have been revealed, including low drug loading capacity, low entrapment efficiency, short half-life, loss of bioactivity, and undesirable side effects5,6,7,8. Effective carrier systems remain an area of research interest. Moreover, the development of analytical methods to characterize drug-loaded NPs is more challenging for macromolecules than for small molecules.

High-density lipoprotein (HDL) is a natural NP composed of a lipid core that is coated by apolipoproteins and a phospholipid monolayer. Endogenous HDL plays a critical role in the transport of lipids, proteins, and nucleic acids through its interaction with target receptors, such as SR-BI, ABCAI, and ABCG1. It has been explored as a vehicle for the delivery of different therapeutic agents9,10,11,12. Various methods have been developed to prepare HDL-mimicking NPs. Dialysis is a popular approach. In this method, NPs are formed by hydrating a lipid film using sodium cholate solution. The salt is then removed through a 2-day dialysis with three buffers13. Sonication methods fabricate NPs by sonicating a lipid mixture for 60 min under a heating condition; the NPs are further purified through gel chromatography14. Microfluidics generates NPs via a microfluidic device, which mixes phospholipids and apolipoprotein A-I (Apo A-I) solutions by creating microvortices in a focusing pattern15. Clearly, these methods can be time consuming, harsh, and difficult for industrial scale-up.

In this article, we introduce the preparation and characterization of novel HDL-mimicking NPs for nerve growth factor (NGF) encapsulation. NGF is a disulfide-linked polypeptide homodimer containing two 13.6-kDa polypeptide monomers. A novel procedure to prepare the NPs by homogenization, followed by the encapsulation of NGF into the NPs, was developed. The NGF HDL-mimicking NPs were characterized for particle size, size distribution, zeta potential, and in vitro release. Their bioactivity was evaluated for neurite outgrowth in PC12 cells. The biodistribution of NGF HDL-mimicking NPs was compared with that of free NGF after intravenous injection in mice.

Access restricted. Please log in or start a trial to view this content.

Protocol

NOTE: The animal studies included in all procedures have been approved by the Institutional Animal Care and Use Committee at the University of North Texas Health Science Center.

1. Preparation of NGF HDL-mimicking Nanoparticles

  1. Dissolve the excipients, phosphatidylcholine (PC), sphingomyelin (SM), phosphatidylserine (PS), cholesteryl oleate (CO), and D-α-tocopheryl polyethylene glycol succinate (TPGS), in ethanol to prepare stock solutions at 1 mg/mL.
    NOTE: The stock solutions were aliquoted and stored at -20 °C. The cholesteryl oleate was stored in dark bottles. The PC, SM, PS, and CO stock solutions were stable for up to 6, 3, 12, and 12 months, respectively, at -20 °C. The TPGS solution was stable for at least 12 months at -20 °C.
  2. Mix 10 µL of NGF (1 mg/mL in water) with 10 µL of protamine USP (1 mg/mL in water) in a 1.5 mL microcentrifuge tube and let it stand for 10 min at room temperature to form the complex.
    NOTE: The NGF and protamine stock solutions were aliquoted and stored at -20 °C. Repeated freezing and thawing is not recommended for the NGF stock.
  3. Add 59 µL of PC, 11 µL of SM, 4 µL of PS, 15 µL of CO, and 45 µL of TPGS to a glass vial. Mix and evaporate the ethanol under a gentle nitrogen stream for about 5 min; all excipients should form an oily, thin film at the bottom of the glass vial.
  4. Add 1 mL of ultrapure (type 1) water to the vial and homogenize at 9,500 rpm (8,600 x g) for 5 min at room temperature to form the prototype NPs.
  5. Add the complex prepared in step 1.2 to the prototype NPs and incubate at 37 °C for 30 min with stirring by using a small stirring bar in the glass vial.
    1. Cool the NPs down by stirring at room temperature for another 30 min. After this cools, add 106 µL of Apo A-I (1.49 mg/mL) and stir at room temperature overnight to form the final NGF HDL-mimicking NPs.

2. Characterization of NGF HDL-mimicking Nanoparticles

  1. Measure the particle size and zeta potential using a particle analyzer (see the Materials Table) as per the manufacturer's instructions.
  2. Use a cross-linked agarose gel filtration chromatography column to separate the unloaded NGF from the NGF HDL-mimicking NPs and determine the entrapment efficiency of the NGF.
    1. For the column preparation, transfer 15 mL of Sepharose 4B-CL suspension to a 50-mL beaker. Stir the bead suspension using a glass rod and pour some into a column (30 cm length × 1 cm diameter, with a glass frit at the bottom). Gently tap the column to get rid of bubbles. Allow the solvent to drain and the beads to settle for a few min.
    2. Continue to add the remaining suspension. Rinse the inside wall of column to clean the beads. Drain the solvent until the solvent level is slightly above the top of the stationary phase. Wash and condition the column with 20 mL of 1x phosphate-buffered saline (PBS, containing 137 mM NaCl, 2.7 mM KCl, 8 mM Na2HPO4, and 2 mM KH2PO4).
    3. To determine the fractions containing unloaded NGF, load 200 µL of NGF solution (10 µg/mL) onto the gel filtration column (25 cm length x 1 cm diameter) and elute with 1x PBS.
    4. Collect a total of 12 fractions (1 mL for each fraction) and measure the concentration of NGF in each fraction using a Sandwich ELISA kit for NGF.
    5. Detect NGF from fractions 6 to 10 using the Sandwich ELISA kit. Obtain a chromatogram of unloaded NGF on the column. Wash the column with 20 mL of PBS.
    6. To determine the fractions containing NGF HDL-mimicking NPs, load 200 µL of the NPs onto the column and elute with 1x PBS. Collect a total of 12 fractions (1 mL for each fraction) and measure the intensity of particles in each fraction using the particle size analyzer. Detect the NGF NPs from fractions 2 to 4.
      NOTE: The intensity is a parameter measured by the particle analyzer, which tells how many nanoparticles may exist in the test solution. The more NPs exist in solution, the higher the intensity is. By this approach, we can confirm that the column can separate NGF NPs from unloaded NGF.
    7. To measure the entrapment efficiency of NGF, load 200 µL of NGF HDL-mimicking NPs onto the column and elute with 1x PBS. Collect a total of 12 fractions (1 mL for each fraction).
    8. Measure the unloaded NGF concentration from fractions 6 to 10 using the Sandwich ELISA kit.
    9. Add the NGF amounts measured from fractions 6 to 10 together as the unloaded NGF and calculate the entrapment efficiency of NGF using the following equation.
      %EE = (1 - unloaded NGF/total NGF added into NP) x 100% Equation (1)

3. In Vitro Release of NGF HDL-mimicking Nanoparticles

  1. Study free NGF (10 µg/mL in water; n = 4) and NGF HDL-mimicking NPs (10 µg/mL; n = 4) in parallel.
  2. Pre-treat 8 dialysis tubes (molecular weight cutoff: 300 kDa) by following the manufacturer's instructions.
  3. Prepare 5% bovine serum albumin (BSA) in PBS as the release medium. Add 30 mL of release medium to a 50-mL centrifuge tube and warm it up to 37 °C in a shaker with a 135 rpm shaking speed. Place another 50 mL of release medium in the shaker for replacement.
  4. Add 400 µL of release medium into the dialysis tube and quickly add 200 µL of the tested sample to make enough volume for dialysis.
  5. Close the tube and quickly put the dialysis tube into the release medium (the centrifuge tube). Quickly withdraw 100 µL of the release medium from the outside dialysis tube as the sample for time 0. Immediately put the sample into -20 °C for later analysis. Add 100 µL of fresh release medium into the centrifuge tube to replace the withdrawn sample. Start the timer.
  6. At 1, 2, 4, 6, 8, 24, 48, and 72 h, withdraw 100 µL of the release medium and replace it with 100 µL of fresh medium. Immediately put the withdrawn samples into -20 °C for later analysis.
  7. After 72 h, take out all samples from -20 °C and thaw them at room temperature. Measure the NGF concentrations of the release samples using the Sandwich ELISA kit.

4. Bioactivity of NGF HDL-mimicking Nanoparticles (Neurite Outgrowth Study)

  1. Culture PC12 cells in RPMI-1640 medium supplemented with 10% heat-inactivated horse serum, 5% fetal bovine serum, 100 µg/mL streptomycin, and 100 units/mL penicillin. Maintain the cells in a humidified incubator at 37 °C and with 5% CO2.
  2. When the cells reach ~70-80% confluence, remove the culture medium and wash the cells with 1x PBS (approximately 2 mL per 10 cm2 culture surface area). Remove the wash solution. Trypsinize the cells by adding 0.25% Trypsin-EDTA solution (0.25% trypsin and 1 mM EDTA; 0.5 mL per 10 cm2 culture surface area) to the flask and incubate at 37 °C until most cells are detached.
  3. Add two volumes of culture medium and spin down at 180 x g for 5 min. Remove the supernatant and resuspend the cell pellet in 5 mL of culture medium. Filter the cells through a 22 G, ½ inch needle to break cell clusters.
  4. Split the cells at a ratio of 1:3 into a new cell culture flask. After incubating overnight, remove unattached PC12 cells. Allow the attached cells to remain for further growth.
  5. Repeat this procedure for 3 passages to select the subculture of PC12 that has a strong adhesion property. Pre-coat a 6-well plate with 800 µL/well of rat tail collagen type I (100 µg/mL).
  6. Trypsinize the selected PC12 cells as described in step 4.2 and filter them through a 22 G, ½ inch needle to break the cell clusters. Count the cells with a hemocytometer. Seed the cells overnight at a density of 10,000 cells/well in the pre-coated 6-well plate in step 4.5 to allow the cells to attach to the plate.
  7. Dilute free NGF (10 µg/mL) and NGF HDL-mimicking NPs (10 µg/mL) with the culture medium (described in step 4.1) to prepare 0.5, 1, 5, 10, 50, and 100 ng/mL concentrations. Remove 2 mL of medium from each well and replace with 2 mL of the diluted free NGF or NGF HDL-mimicking NPs. Culture for 4 days.
  8. On day 4, change the medium to fresh medium (described in step 4.1) containing the corresponding treatment and continue the treatment for another 3 days.
  9. On day 7, visualize the cells with an inverted light microscope and image each well at random spots under 10X magnification.

5. Biodistribution of NGF HDL-mimicking Nanoparticles

  1. Use adult BALB/c mice (male, 25-30 g) to test the tissue distribution of NGF NPs. Randomly divide the mice into three groups of 3 mice per group. Use a cone-shaped plastic restraint (e.g., decapicone) to restrain a mouse and wipe the tail with ethanol to promote vasodilation and the visibility of the vein.
  2. Inject 100 µL of either saline, free NGF, or NGF HDL-mimicking NPs to each group of mice (3 groups) through the tail veins at a dose of 40 µg/kg of NGF. Use a 30½ G needle attached to a 1 mL syringe.
  3. At 30 min after the injection, anesthetize the mice using 3% inhaled isoflurane (in oxygen at flow rate of 2 L/min). Perform a tail and toe pinch to determine the depth of anesthesia. Collect blood by cardiac puncture.
    1. Withdraw approximately 1 mL of blood from the heart. Euthanize each mouse by cervical dislocation.
  4. Place the mouse carcass in dorsal recumbency. Open the abdomen using surgical scissors and move fat and intestine aside using a cotton swab to expose the liver, spleen, and kidney. Harvest these tissues and rinse them in 1x PBS to clean the blood.
  5. Immediately centrifuge the blood samples at 3,400 x g and 4 °C for 5 min to obtain the plasma. Store the plasma and tissues at -80 °C until the analyses.
  6. To analyze the tissue samples, move the samples from -80 °C to 4 °C and suspend 100 mg of tissue sample in a 10x volume of extraction buffer (0.05 M sodium acetate, 1.0 M sodium chloride, 1% triton X-100, 1% BSA, 0.2 mM phenylmethanesulfonyl fluoride, and 0.2 mM benzethonium chloride). Homogenize at 10,000 rpm and 4 °C for 5 min.
  7. Sacrifice two untreated mice to collect blank plasma and tissues, as described in steps 5.3 and 5.4. Prepare NGF standard solutions using blank plasma or blank tissue homogenates.
  8. Determine the concentrations of NGF in the plasma and tissue homogenates using the Sandwich ELISA kit, as described above.

Access restricted. Please log in or start a trial to view this content.

Results

The engineering scheme of HDL-mimicking, α-tocopherol-coated NGF NPs prepared by an ion-pair strategy is shown in Figure 1. To neutralize the surface charges of NGF, protamine USP was used as an ion-pair agent to form a complex with NGF. To protect the bioactivity, prototype HDL-mimicking NPs were engineered, first using homogenization; then, the NGF/protamine complex was encapsulated into the prototype NPs. Homogenization provided sufficient energy and successfully ...

Access restricted. Please log in or start a trial to view this content.

Discussion

In this study, we demonstrate a simple method to prepare HDL-mimicking NPs for NGF encapsulation. Various NP delivery systems have been studied to deliver proteins. Currently, many NP preparations involve dialysis, solvent precipitation, and film hydration. These processes are generally complicated and challenging upon scale-up. During this NP development, it was determined that the lipids had strong adhesion to the glass wall of the container, which led to the difficulties in hydrating the thin film and efficiently mixi...

Access restricted. Please log in or start a trial to view this content.

Disclosures

The authors have nothing to disclose.

Acknowledgements

This work was supported by NIH R03 NS087322-01 to Dong, X.

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
Recombinant Human Beta-NGFCreative BiomartNGF-05H
L-α-Phosphatidylcholine (PC)Avanti131601P95%, Egg, Chicken
Sphingomyelin (SM)Avanti860062PBrain, Porcine
Phosphatidylserine (PS)Avanti840032PBrain, Porcine
Cholesteryl oleate (CO)SigmaC9253
D-α-Tocopheryl polyethylene glycol succinate (TPGS)BASF9002-96-4Vitamin E Polyethylene Glycol Succinate
Protamine sulfateSigmaP3369meets USP testing specifications
Apolipoprotein A1, Human plasmaAthens Research & Technology16-16-1201011 mg in 671 µL 10 mM NH4HCO3, pH 7.4
Sepharose 4B-CLSigmaCL4B200Cross-linked agarose,  gel filtration chromatography column filling material
Sandwich ELISA Kit for NGFR&D systemDY008
Bovine Serum AlbuminSigmaA2153
RPMI-1640 mediumGE Healthcare Life ScienceSH30096.02
Horse serumGE Healthcare Life ScienceSH30074.03
Fetal bovine serumGibco10082147
PC12 cellsATCCCRL-1721
Rat tail collagen type ISigmaC3867
Sodium acetateSigmaS2889
Sodium chlorideSigma31414
Triton X-100SigmaT8787
Phenylmethanesulfonyl fluoride (PMSF)SigmaP7626
Benzethonium chlorideSigmaB8879
NameCompanyCatalog NumberComments
Equipment
HomogenizerTekmarT 25-S1
Delsa Nano HC particle analyzerBeckman-CoulterDelsa Nano HC
Float-A-Lyzer G2 Dialysis DeviceSpectrum LaboratoriesG235036Molecule Cutoff 300 kDa
CentrifugeEppendoff5424R
Polytron homogenizerKinematicaPT 1200C
DecapiCone Braintree Scientific Inc.DC-M200

References

  1. Bruno, B. J., Miller, G. D., Lim, C. S. Basics and recent advances in peptide and protein drug delivery. Ther Deliv. 4 (11), 1443-1467 (2013).
  2. Mo, Z. C., Ren, K., Liu, X., Tang, Z. L., Yi, G. H. A high-density lipoprotein-mediated drug delivery system. Adv Drug Deliv Rev. 106 (Pt A), 132-147 (2016).
  3. Lacko, A. G., Sabnis, N. A., Nagarajan, B., McConathy, W. J. HDL as a drug and nucleic acid delivery vehicle. Front Pharmacol. 6, 247-252 (2015).
  4. Vaishya, R., Khurana, V., Patel, S., Mitra, A. K. Long-term delivery of protein therapeutics. Expert Opin Drug Deliv. 12 (3), 415-440 (2015).
  5. Lasic, D. D., Papahadjopoulos, D. Medical application of liposomes. , Elsevier. (1998).
  6. Samad, A., Sultana, Y., Aqil, M. Liposomal drug delivery systems: an update review. Curr Drug Deliv. 4 (4), 297-305 (2007).
  7. Bezemer, J. M., Radersma, R., Grijpma, D. W., Dijkstra, P. J., van Blitterswijk, C. A., Feijen, J. Microspheres for protein delivery prepared from amphiphilic multiblock copolymers: 2. Modulation of release rate. J Control Release. 67 (2-3), 249-260 (2000).
  8. Patel, A., Patel, M., Yang, X., Mitra, A. K. Recent advances in protein and peptide drug delivery: a special emphasis on polymeric nanoparticles. Protein Pept lett. 21 (11), 1102-1120 (2014).
  9. Kuai, R., Li, D., Chen, Y. E., Moon, J. J., Schwendeman, A. High-density lipoproteins: nature's multifunctional nanoparticles. ACS Nano. 10 (3), 3015-3041 (2016).
  10. Gursky, O. Structural stability and functional remodeling of high-density lipoproteins. FEBS Lett. 589 (19 Pt A), 2627-2639 (2015).
  11. McMahon, K. M., Thaxton, C. S. High-density lipoproteins for the systemic delivery of short interfering RNA. Expert Opin Drug Deliv. 11 (2), 231-247 (2014).
  12. McMahon, K. M., Foit, L., Angeloni, N. L., Giles, F. J., Gordon, L. I., Thaxton, C. S. Synthetic high-density lipoprotein-like nanoparticles as cancer therapy. Cancer Treat Res. 166, 129-150 (2015).
  13. Lerch, P. G., Förtsch, V., Hodler, G., Bolli, R. Production and characterization of a reconstituted high density lipoprotein for therapeutic applications. Vox Sang. 71 (3), 155-164 (1996).
  14. Zhang, Z., Chen, J., Ding, L., Jin, H., Lovell, J. F., Corbin, I. R., Cao, W., Lo, P. C., Yang, M., Tsao, M. S., Luo, Q., Zheng, G. HDL-mimicking peptide-lipid nanoparticles with improved tumor targeting. Small. 6 (3), 430-437 (2010).
  15. Kim, Y., Fay, F., Cormode, D. P., Sanchez-Gaytan, B. L., Tang, J., Hennessy, E. J., Ma, M., Moore, K., Farokhzad, O. C., Fisher, E. A., Mulder, W. J., Langer, R., Fayad, Z. A. Single step reconstitution of multifunctional high-density lipoprotein-derived nanomaterials using microfluidics. ACS Nano. 7 (11), 9975-9983 (2013).
  16. Prathipati, P., Zhu, J., Dong, X. D. Development of novel HDL-mimicking α-tocopherol-coated nanoparticles to encapsulate nerve growth factor and evaluation of biodistribution. Eur J Pharm and Biopharm. 108, 126-135 (2016).

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Request permission to reuse the text or figures of this JoVE article

Request Permission

Tags

Nanoparticle PreparationHomogenization MethodParticle Size AnalysisGel Filtration ChromatographyEntrapment EfficiencyIn Vitro ReleaseNeurite OutgrowthApolipoprotein A I

Related Articles